OR WAIT null SECS
The American College of Rheumatology (ACR) has published guidance regarding COVID-19 vaccination for patients with rheumatic diseases, with emphasis placed on supplemental and booster doses for patients with rheumatic disease.
The American College of Rheumatology (ACR) has published guidance regarding COVID-19 vaccination for immunocompromised patients, with emphasis placed on supplemental and booster doses, recommendations for the timing of those injections concerning immunomodulatory medication, and pre- and post-exposure prophylaxis with monoclonal antibody treatment.
The ACR curated the North American Task Force panel, consisting of 9 rheumatologists, 2 infectious disease specialists, and 2 public health experts. The panelists created a list of clinical questions and that were then rated with a numerical score on level of agreement. Only questions with “moderate” (M) or “high” (H) agreement and importance were included in the draft.
“It remains important for rheumatology providers to assess the vaccination status of all patients with rheumatic diseases,” Jeffrey Curtis, MD, Chair of the ACR COVID-19 Vaccine Guidance Task Force, stated. “Initially, it might have been acceptable to just ask a patient if they have been vaccinated. There is now more nuance with supplemental and booster dose recommendations that should prompt us to ask patients not only whether they have been vaccinated, but with what, how many times, and how recently.”
Changes in the 5th version of the guidelines are listed below: